Pieris Pharmaceuticals, Inc.
PIRS
|
$0.1698
-1.11%
-1.12%
560K
|
Health Technology
(0.0% 1d) (-19.0% 1m) (-79.4% 1y) (0.0% 2d) (0.0% 3d) (-4.1% 7d) (141.03% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 16,799,167
http://www.pieris.com
Sec Filling | Patents | 127 employees
(US) Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.
respiratory urea anemia
add to watch list Paper trade email alert is off
Press-releases
Soleno Therapeutics Strengthens Leadership Team with Key Appointments
Published: 2024-01-24 (Crawled : 13:00) - globenewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -3.01%
H: 0.69%
C: -0.75%
VYGR | $8.25 -2.14% -2.18% 450K
|
Health Technology
|
| O: 1.19%
H: 0.33%
C: -2.61%
SLNO 4 | $38.52 3.72% 3.58% 290K
|
Health Technology
|
| O: -1.62%
H: 1.53%
C: -2.07%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: -3.23%
H: 4.2%
C: -1.3%
FULC | $7.35 -5.89% -6.26% 440K
|
Health Technology
|
| O: 1.04%
H: 2.28%
C: -1.33%
key therapeutics
Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
Published: 2023-08-17 (Crawled : 13:00) - biospace.com/
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: 5.11%
H: 10.24%
C: 2.81%
bos-342 pharmaceuticals milestone study
Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring
Published: 2023-07-18 (Crawled : 13:20) - biospace.com/
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: 33.55%
H: 47.44%
C: -16.28%
update pharmaceuticals
Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study
Published: 2023-06-21 (Crawled : 12:00) - biospace.com/
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: -58.66%
H: 5.38%
C: -29.51%
prs-060 pharmaceuticals trial study
Pieris Pharmaceuticals to Present at Jefferies 2023 Healthcare Conference
Published: 2023-06-02 (Crawled : 22:00) - biospace.com/
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: 0.0%
H: 5.88%
C: 5.35%
conference pharmaceuticals
Pieris Pharmaceuticals Announces Presentation of Encouraging Preclinical Data for PRS-400 at ATS 2023 International Conference
Published: 2023-05-22 (Crawled : 14:00) - biospace.com/
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: 1.34%
H: 4.59%
C: 4.59%
prs-400 conference presentation international pharmaceuticals preclinical
OMass Therapeutics Announces Appointment of New Board Chair and Series B Extension
Published: 2023-05-15 (Crawled : 10:00) - biospace.com/
VYGR | $8.25 -2.14% -2.18% 450K
|
Health Technology
|
| O: -0.86%
H: 0.97%
C: 0.48%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: 0.0%
H: 4.64%
C: 0.57%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: 6.61%
H: 4.01%
C: -1.82%
FULC | $7.35 -5.89% -6.26% 440K
|
Health Technology
|
| O: 4.28%
H: 7.62%
C: 6.74%
extension therapeutics
Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Updates
Published: 2023-05-10 (Crawled : 12:00) - biospace.com/
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: -1.76%
H: 4.19%
C: 2.99%
business pharmaceuticals financial results
Pieris Pharmaceuticals Announces Successful Completion of Safety Review for 10 mg Dose of Phase 2a Trial of Elarekibep (PRS-060/AZD1402)
Published: 2023-05-04 (Crawled : 13:20) - biospace.com/
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: 0.7%
H: 5.53%
C: -2.97%
prs-060 review pharmaceuticals trial
Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting
Published: 2023-04-17 (Crawled : 13:00) - biospace.com/
PIRS | $0.1698 -1.11% -1.12% 560K
|
Health Technology
|
| O: 10.01%
H: 5.32%
C: 4.43%
prs-343 presentation positive pharmaceuticals meeting
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Last 48 Hours Insiders Buying
RMCF | $3.56 -7.2% 7.1K
|
Consumer Non-Durables
|
20:10